A clinical trial for the drug Jusvinza, developed by the Center for Genetic Engineering and Biotechnology (CIGB) for the treatment of residual polyarthritis in patients recovering from chikungunya, has begun in the Cuban province of Matanzas.

Taking place at the Comandante Faustino Pérez Clinical-Surgical-Teaching Hospital in this western Cuban territory, the research aims to evaluate the drug's efficacy in reducing joint pain and inflammation.

According to the website www.radio26.cu, the study includes individuals who had chikungunya and maintained joint symptoms for more than three months. Participants, aged 19 to 80, were selected under specific criteria to ensure greater effectiveness in the trial's results.

Treatment with Jusvinza consists of nine subcutaneous doses administered over six weeks. In the first week, three consecutive doses are administered; in the second week, two doses; and from the third to the sixth week, one dose per week, explained Dr. Yudisay Reyes, an Oncology specialist and member of the CIGB Clinical Research Group.

For the administration of this regimen, treatment can be carried out on an outpatient or hospitalized basis, depending on the patient's clinical situation and place of residence, especially for those living far from the Faustino Pérez Hospital, she stated.

The press outlet states that the trial includes 120 patients divided into two groups of 60: one will receive Jusvinza alongside conventional treatment, and another will continue solely with the standard therapy. (CubaSí)